0.55
-8.19%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About 60 Degrees Pharmaceuticals
From its filings with the US Securities and Exchange Commission
60 Degrees Pharmaceuticals is based in Washington, Washington, DC and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker SXTP. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $1.0m and a net loss of $7.4m. At that date it held total assets of $5.4m and shareholders' equity of $3.5m.
We are a specialty pharmaceutical company with a goal of using cutting-edge biological science and applied research to further develop and commercialize new therapies for the prevention and treatment of infectious diseases. We have successfully achieved regulatory approval of Arakoda, a malaria preventative treatment that has been on the market since late 2019. Currently, 60P’s pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company’s future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.
60 Degrees Pharmaceuticals, Inc. is a Delaware corporation that was incorporated on June 1, 2022. On June 1, 2022, 60 Degrees Pharmaceuticals, LLC, a District of Columbia limited liability company (“60P LLC”), entered into the Agreement and Plan of Merger with 60 Degrees Pharmaceuticals, Inc., pursuant to which 60P LLC merged into 60 Degrees Pharmaceuticals, Inc. The value of each outstanding membership interest in 60P LLC was correspondingly converted into common stock of 60 Degrees Pharmaceuticals, Inc., par value $0.0001 per share, with a cost-basis equal to $1,200.00 per share.
Quoted from its 10-K, filed 30 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 12 Jul 2023
- Employees
- 2
- Website
- 60degreespharma.com ↗
- Head office
- 1025 CONNECTICUT AVENUE NW, WASHINGTON, DC, 20036
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- <br>Emerging growth company
Leadership
Pay as last reported
- Dr. Geoffrey DowPresident, Chief Executive Officer, Director$323,425
- Mr. Tyrone MillerChief Financial Officer$284,525
- Ms. Kristen LandonChief Commercial Officer$470,862
- Ms. Cheryl XuDirector$65,912
- Mr. Charles AllenIndependent Director$73,912
- Mr. Paul FieldIndependent Director$70,912
- Dr. Stephen TooveyIndependent Director$70,912
- Mr. Patrick GaynesInvestor Relations Officer
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Lead product ARAKODA is in Phase II for mild-moderate COVID-19 treatment.
- Company has two full-time employees focused on infectious disease therapies.
- Pipeline includes Arakoda regimen for malaria and new products for viral diseases.
Weaknesses
- Company has only two employees limiting operational capacity.
- IPO listing date 12 July 2023 indicates recent market entry.
- Headquarters in Washington, D.C. may limit access to major pharmaceutical hubs.
Opportunities
- ARAKODA regimen shows potential for malaria prophylaxis in patients over 18.
- Celgosivir development targets multiple viral diseases including RSV and dengue.
- Clinical study planned for ARAKODA treatment of human babesiosis.
Threats
- Phase II study data for ARAKODA in mild-moderate COVID-19 requires further validation.
- Pipeline development for fungal and tick-borne diseases faces regulatory hurdles.
- Competition in antimalarial market could impact ARAKODA's commercial success.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.